Cargando…

Vitamin D in Chronic Kidney Disease and Dialysis Patients

Vitamin D deficiency (<20 ng/mL) and insufficiency (20–29 ng/mL) are common among patients with chronic kidney disease (CKD) or undergoing dialysis. In addition to nutritional and sunlight exposure deficits, factors that affect vitamin D deficiency include race, sex, age, obesity and impaired vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jean, Guillaume, Souberbielle, Jean Claude, Chazot, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409667/
https://www.ncbi.nlm.nih.gov/pubmed/28346348
http://dx.doi.org/10.3390/nu9040328
_version_ 1783232517487198208
author Jean, Guillaume
Souberbielle, Jean Claude
Chazot, Charles
author_facet Jean, Guillaume
Souberbielle, Jean Claude
Chazot, Charles
author_sort Jean, Guillaume
collection PubMed
description Vitamin D deficiency (<20 ng/mL) and insufficiency (20–29 ng/mL) are common among patients with chronic kidney disease (CKD) or undergoing dialysis. In addition to nutritional and sunlight exposure deficits, factors that affect vitamin D deficiency include race, sex, age, obesity and impaired vitamin D synthesis and metabolism. Serum 1,25(OH)(2)D levels also decrease progressively because of 25(OH)D deficiency, together with impaired availability of 25(OH)D by renal proximal tubular cells, high fibroblast growth factor (FGF)-23 and decreased functional renal tissue. As in the general population, this condition is associated with increased morbidity and poor outcomes. Together with the progressive decline of serum calcitriol, vitamin D deficiency leads to secondary hyperparathyroidism (SHPT) and its complications, tertiary hyperparathyroidism and hypercalcemia, which require surgical parathyroidectomy or calcimimetics. Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) experts have recognized that vitamin D insufficiency and deficiency should be avoided in CKD and dialysis patients by using supplementation to prevent SHPT. Many vitamin D supplementation regimens using either ergocalciferol or cholecalciferol daily, weekly or monthly have been reported. The benefit of native vitamin D supplementation remains debatable because observational studies suggest that vitamin D receptor activator (VDRA) use is associated with better outcomes and it is more efficient for decreasing the serum parathormone (PTH) levels. Vitamin D has pleiotropic effects on the immune, cardiovascular and neurological systems and on antineoplastic activity. Extra-renal organs possess the enzymatic capacity to convert 25(OH)D to 1,25(OH)(2)D. Despite many unanswered questions, much data support vitamin D use in renal patients. This article emphasizes the role of native vitamin D replacement during all-phases of CKD together with VDRA when SHPT persists.
format Online
Article
Text
id pubmed-5409667
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54096672017-05-03 Vitamin D in Chronic Kidney Disease and Dialysis Patients Jean, Guillaume Souberbielle, Jean Claude Chazot, Charles Nutrients Review Vitamin D deficiency (<20 ng/mL) and insufficiency (20–29 ng/mL) are common among patients with chronic kidney disease (CKD) or undergoing dialysis. In addition to nutritional and sunlight exposure deficits, factors that affect vitamin D deficiency include race, sex, age, obesity and impaired vitamin D synthesis and metabolism. Serum 1,25(OH)(2)D levels also decrease progressively because of 25(OH)D deficiency, together with impaired availability of 25(OH)D by renal proximal tubular cells, high fibroblast growth factor (FGF)-23 and decreased functional renal tissue. As in the general population, this condition is associated with increased morbidity and poor outcomes. Together with the progressive decline of serum calcitriol, vitamin D deficiency leads to secondary hyperparathyroidism (SHPT) and its complications, tertiary hyperparathyroidism and hypercalcemia, which require surgical parathyroidectomy or calcimimetics. Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) experts have recognized that vitamin D insufficiency and deficiency should be avoided in CKD and dialysis patients by using supplementation to prevent SHPT. Many vitamin D supplementation regimens using either ergocalciferol or cholecalciferol daily, weekly or monthly have been reported. The benefit of native vitamin D supplementation remains debatable because observational studies suggest that vitamin D receptor activator (VDRA) use is associated with better outcomes and it is more efficient for decreasing the serum parathormone (PTH) levels. Vitamin D has pleiotropic effects on the immune, cardiovascular and neurological systems and on antineoplastic activity. Extra-renal organs possess the enzymatic capacity to convert 25(OH)D to 1,25(OH)(2)D. Despite many unanswered questions, much data support vitamin D use in renal patients. This article emphasizes the role of native vitamin D replacement during all-phases of CKD together with VDRA when SHPT persists. MDPI 2017-03-25 /pmc/articles/PMC5409667/ /pubmed/28346348 http://dx.doi.org/10.3390/nu9040328 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jean, Guillaume
Souberbielle, Jean Claude
Chazot, Charles
Vitamin D in Chronic Kidney Disease and Dialysis Patients
title Vitamin D in Chronic Kidney Disease and Dialysis Patients
title_full Vitamin D in Chronic Kidney Disease and Dialysis Patients
title_fullStr Vitamin D in Chronic Kidney Disease and Dialysis Patients
title_full_unstemmed Vitamin D in Chronic Kidney Disease and Dialysis Patients
title_short Vitamin D in Chronic Kidney Disease and Dialysis Patients
title_sort vitamin d in chronic kidney disease and dialysis patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409667/
https://www.ncbi.nlm.nih.gov/pubmed/28346348
http://dx.doi.org/10.3390/nu9040328
work_keys_str_mv AT jeanguillaume vitamindinchronickidneydiseaseanddialysispatients
AT souberbiellejeanclaude vitamindinchronickidneydiseaseanddialysispatients
AT chazotcharles vitamindinchronickidneydiseaseanddialysispatients